期刊文献+

泮托拉唑钠肠溶微丸胶囊的制备 被引量:2

Preparation of the enteric-coated pellets of pantoprazole sodium
下载PDF
导出
摘要 以泮托拉唑钠、聚乙烯吡咯烷酮、滑石粉、磷酸钠、磷酸氢二钠和水混合制成主药层包衣溶液。采用流化床包衣技术,对空白丸芯依次包主药层、隔离层和肠溶层,制得泮托拉唑钠肠溶微丸,并优化了处方和工艺。将所得肠溶微丸装入普通胶囊中制成泮托拉唑钠肠溶微丸胶囊。3批制品在pH 6.8磷酸盐缓冲液中30 min时释放度分别为91.74%、87.98%、88.31%,在0.1 mol/L盐酸中2 h时的耐酸力分别为98.71%、97.18%、101.5%。 The drug layer coating solution was made by mixing pantoprazole sodium, PVP, TALC, sodium phosphate and sodium hydrogen phosphate with water. The blank pellets were consecutively coated with drug layer, insulation layer and enteric layer to obtain pantoprazole sodium enteric-coated pellets in fluidized bed. Meanwhile, the formulation and process were optimized. The pantoprazole sodium enteric capsules were prepared by encapsulating enteric-coated pellets into hard gelatin capsules. The accumulative release of three batches of the capsules in pH 6.8 phosphate buffer at 30 min were 91.74%, 87.98% and 88.31% and their acid tolerance rates in 0.1 mol/L hydrochloric acid at 2 h were 98.71%, 97.18%a nd 101.5%, respectively.
作者 董佳丽 黄震
出处 《上海医药》 CAS 2014年第21期74-77,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 泮托拉唑钠 肠溶微丸 流化床包衣 pantoprazole sodium enteric-coated pellet fluidized bed coating
  • 相关文献

参考文献7

二级参考文献36

  • 1周学敏,刘杰,高娟,许荔新,姜利民,李凤才.泮托拉唑钠肠溶微丸胶囊人体生物等效性研究[J].中国新药杂志,2006,15(12):1008-1010. 被引量:5
  • 2刘珠,高振强.泮托拉唑钠口腔崩解片的制备及质量控制[J].中国药师,2007,10(1):51-52. 被引量:4
  • 3[1]Anonymous. Pantoprazole--a third pump inhibitor[J]. Drug Ther Bull, 1997,35(2):93-94.
  • 4[2]Sachs C. Proton pump inhibitors and acid-related disease[J]. Pharmaco Therapy, 1997,17(1):22-37.
  • 5[3]Bliesath H, Huber R, Hartmaun H, et al. Dose linearity of the phar-macokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administration [J]. J Clin Pharmacol Ther, 1996,34(Suppl 1):18-24.
  • 6[4]Huber R, Hartmaun M, Bliesath H, et al. Pharmacokinetics of panto-prazole in man[J]. J Clin Pharmacol Ther, 1996,34((Suppl 1): 7-16.
  • 7[5]Wurzer H, Sohutze K, Bethke T, et al . Efficacy and safety of panto-prazole in patients with gastroesophageal reflux disease using in intravenous-oral regim[J]. Hepatogastroent, 1999,46:1809-1815.
  • 8[6]Paul J, Metz D, Marton P, et al. Pharmacodynamic equivalence of oral and iv pantoprazole in GERD patients[J]. Am J Gastroenterol, 1998,93:1622, Abstract.
  • 9[7]Metz D C, Forsmark C E, Soffer E, et al. Zollinger-Ellison syndrome patients can replace oral proton pump inhibitors with intravenous pantoprazole without losing control of acid output[N]. Paper Presented at Digestive Disease Week. 1999-05-16(19).
  • 10[8]Koop H, Kuly Schepp W, Dammann H G. Comparative trial of panto-prazole and ranitidine in the treatment of reflux esophagitis results of a German multicenter study[J]. J Clin Gastroenterol, 1995,20(3):192-195.

共引文献48

同被引文献17

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部